Please login to the form below

Not currently logged in
Email:
Password:

Sutro Biopharma hires chief business officer and VP research

Dr Jeremy Bender and Dr Aaron Sato join as company prepares to advance antibody development

Sutro Biopharma has appointed Dr Jeremy Bender as chief business officer and Dr Aaron Sato as VP, research, as it prepares to advance development of its cancer antibodies.

Dr Bender joins from Allos Therapeutics, where he was VP, corporate development, responsible for mergers and acquisitions, financing transactions, product in-and out-licensing and strategic planning.

During his time at Allos, he set up a collaboration with Mundipharma for the co-development and commercialisation of lymphoma therapy Folotyn (pralatrexate) outside the US and Canada.

He was also heavily involved in the acquisition of Allos by Spectrum Pharmaceuticals.

Dr Sato joins Sutro from OncoMed Pharmaceuticals, where he served as senior director of antibody engineering.

Prior to this, Dr Sato held director positions at Dyax, where he oversaw multiple external collaborations with major pharmaceutical companies.

"Dr Bender's broad skill set in corporate business development and strategic collaborations will help us maximise the select business opportunities we are actively pursuing,” said William Newell, CEO of Sutro.

“Dr Sato's expertise in antibody and protein engineering and phage display driven discovery is important to Sutro's design and development of next-generation antibody drug conjugates and bifunctional antibody-based therapeutics."

26th October 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

A new reality for healthcare
When mobile phones came onto the mass market it would have been difficult to see how they were to develop into the ubiquitous multimedia devices they are now. Their power,...
Digital-green-grey.jpg
Are you getting these benefits from your digital technology?
Your organisation switched from ‘paper to glass’, buying the latest mobile devices and hiring digital agencies to fill them with eye-catching content. But what happened?...
Alzheimer's: the numbers we cannot forget
In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Infographics